All News
Diagnostic tools in autoinflammatory syndromes
With broader awareness about the disease state, early diagnosis and treatment in autoinflammatory syndromes, and its life threatening complication Macrophage Activation Syndrome, remains a huge unmet need.
FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat
Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc
Read Article
Answering questions on how COVID-19 affects rheumatic patients
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Read Article
Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1
Links:
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with finals! https://t.co/3yLgqqC0Yy
Bharat Kumar BharatKumarMD ( View Tweet)
ARCH study -- n~4100
Romo vs Alendronate x 12 mo
Alendronate 12-24 mo
RRR 38% https://t.co/d0G7x4TqUT
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
Hypophosphatasia
- CPPD/chondrocal, enthesop'y, DISH, exostoses
- DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM
Rx - asfotase alpha- bone targeted replac't Rx
#ACR20 #ACRambassador https://t.co/FJ1355MdKG
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
#ACR20 Abstracts on #ILD
Rituximab in ILD (all observational)
#1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m
#1051 ➡️ 50 with IPAF: >70% stable or improved at 12m
#1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX
#ACRambassador https://t.co/klfVwIH5b6
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Over 20,000 tweets and 65 Million+ Impressions Check out the details at https://t.co/Z6X1EeOsnr https://t.co/OtqWZCiu6h
Steven Echard, CAE StevenEchard ( View Tweet)
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
Links:
The Lancet TheLancet ( View Tweet)
Congrats to Dr @DrDavidKarp on your installation as president of @ACRheum and thanks Dr Ellen Gravallese outgoing president on your outstanding leadership in this year! #ACR20 https://t.co/q0r5URWrEr
Angus Worthing MD AngusWorthing ( View Tweet)
There are a number of important mimics of IgG4-RD that should be considered
🔵ANCA-associated vasculitis
🔵Multicentric Castleman’s disease
🔵Rosai-Dorfman disease
🔵Inflammatory myofibroblastic tumour
🔵Cutaneous plasmacytosis
🔵Erdheim-Chester disease
🔵Malignancy
#ACR20
Chris Wincup chriswincup ( View Tweet)
Check out our article titled Undifferentiated Autoinflammatory Syndrome Called VEXAS by @RheumNow. We recap Saturday's session on autoinflammatory syndromes featuring Dr. Dan Kastner. #ACR20
https://t.co/afNK3UuZef https://t.co/qGvC2ylmjL
Links:
Dr. John Cush RheumNow ( View Tweet)
Want the highlights of #ACR20 Day 4? Check out our podcast through the link below or through Apple and Android podcasts. Just look up "Rheum Now".
https://t.co/EHcrkIxAez https://t.co/K2pzQPcgdB
Links:
Dr. John Cush RheumNow ( View Tweet)
The folly of dietary restriction in contemporary gout? by @RichardPAConway
Dr. Conway discusses the abstracts presented at #ACR20
https://t.co/bJBKXKdftO https://t.co/Y5MXcNJQmS
Links:
Dr. John Cush RheumNow ( View Tweet)
Telemedicine Studies: A Trainee’s Perspective by Mrinalini Dey ( @DrMiniDey )
COVID-19 has shifted face to face to consultations--an important change in rheumatology practice. #ACR20
https://t.co/T2iUwE7XUo https://t.co/AyQ6X2fOJA
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Panelists: @drdavidliew, @ejdein1, @MeralElRamahiMD, @RichardPAConway, @RHEUMarampa, and @jeffsparks
https://t.co/btZKgwvoSn https://t.co/Okdvx9HuNc
Links:
Dr. John Cush RheumNow ( View Tweet)
TAK & GCA differ in vessel involvement when it comes to the 👁👁
> TAK- large vessel lesions
> GCA- small vessel vasculitis
@RheumNow #ACR20 https://t.co/sa4VEvCKOt
sheila RHEUMarampa ( View Tweet)
I would usually be on a Transatlantic flight at this point post-ACR. Going #virtual is great as I never left. What did you miss most about a face to face conference? @RheumNow #ACR20
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr. Cush and Dr. Kavanaugh recaps the #ACR20 meeting during #RheumatologyRoundUp highlighting important studies that were presented during the mtg and how they might impact practices. Log into https://t.co/3hCmtuN7kj to view this and all our videos/news stories. @RheumNow https://t.co/HgiA1QrdIX
Links:
k dao KDAO2011 ( View Tweet)